APA

Melemedjian O. K., Asiedu M. N., Tillu D. V., Sanoja R., Yan J., Lark A., Khoutorsky A., Johnson J., Peebles K. A., Lepow T., Sonenberg N., Dussor G. & Price T. J. (20111124). Targeting adenosine monophosphate-activated protein kinase (AMPK) in preclinical models reveals a potential mechanism for the treatment of neuropathic pain. : Molecular pain.

Chicago

Melemedjian Ohannes K, Asiedu Marina N, Tillu Dipti V, Sanoja Raul, Yan Jin, Lark Arianna, Khoutorsky Arkady, Johnson Jessica, Peebles Katherine A, Lepow Talya, Sonenberg Nahum, Dussor Gregory and Price Theodore J. 20111124. Targeting adenosine monophosphate-activated protein kinase (AMPK) in preclinical models reveals a potential mechanism for the treatment of neuropathic pain. : Molecular pain.

Harvard

Melemedjian O. K., Asiedu M. N., Tillu D. V., Sanoja R., Yan J., Lark A., Khoutorsky A., Johnson J., Peebles K. A., Lepow T., Sonenberg N., Dussor G. and Price T. J. (20111124). Targeting adenosine monophosphate-activated protein kinase (AMPK) in preclinical models reveals a potential mechanism for the treatment of neuropathic pain. : Molecular pain.

MLA

Melemedjian Ohannes K, Asiedu Marina N, Tillu Dipti V, Sanoja Raul, Yan Jin, Lark Arianna, Khoutorsky Arkady, Johnson Jessica, Peebles Katherine A, Lepow Talya, Sonenberg Nahum, Dussor Gregory and Price Theodore J. Targeting adenosine monophosphate-activated protein kinase (AMPK) in preclinical models reveals a potential mechanism for the treatment of neuropathic pain. : Molecular pain. 20111124.